Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jan 18;63(1):2302146.
doi: 10.1183/13993003.02146-2023. Print 2024 Jan.

Reply: Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease

David Zhang  1 , Ayodeji Adegunsoye  2 , Justin M Oldham  3 , Paul J Wolters  4 , Christine Kim Garcia  1 , Chad A Newton  5
Affiliations
Comment

Reply: Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease

David Zhang et al. Eur Respir J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: D. Zhang reports consulting fees from Boehringer Ingelheim, and grant support from the Stony Wold-Herbert Fund and Parker B. Francis Foundation. A. Adegunsoye reports consulting fees from Genentech, Inogen, Medscape, PatientMpower and Boehringer Ingelheim, and grant support from NHLBI. J.M. Oldham reports consulting fees from Boehringer Ingelheim, Lupin Pharmaceuticals, AmMax Bio, Roche and Veracyte, and grant support from NHLBI. P.J. Wolters reports grant support from Boehringer Ingelheim, Roche, Sanofi, Pliant and NIH, and consulting fees from Blade Therapeutics. C.K. Garcia reports grant support from NIH, DOD and Boehringer Ingelheim. C.A. Newton reports consulting fees from Boehringer Ingelheim and grant support from NHLBI.

Comment on

References

    1. Zhang D, Adegunsoye A, Oldham JM, et al. Telomere length and immunosuppression in non-idiopathic pulmonary fibrosis interstitial lung disease. Eur Respir J 2023; 62: 2300441. - PMC - PubMed
    1. Simpson T, Barratt SL, Beirne P, et al. The burden of progressive fibrotic interstitial lung disease across the UK. Eur Respir J 2021; 58: 2100221. - PMC - PubMed
    1. Oldham JM, Lee CT, Wu Z, et al. Lung function trajectory in progressive fibrosing interstitial lung disease. Eur Respir J 2022; 59: 2101396. - PMC - PubMed
    1. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019; 381: 1718–1727. - PubMed
    1. Behr J, Prasse A, Kreuter M, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021; 9: 476–486. - PubMed

LinkOut - more resources